The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Incorporating genetic analyses in the diagnostic pathway of MDS
Moshe Mittelman, MD, Tel Aviv Sourasky (Ichilov) Medical Center, Tel Aviv University, Israel, discusses how the diagnosis of myelodysplastic syndromes (MDS) is changing, explaining that whilst patient history and bone marrow morphology are still important diagnostic tools, genetic analyses are increasingly being used to refine diagnosis and prognosis. This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Research Funding; Takeda: Honoraria, Research Funding; Janssen: Research Funding; Roche: Research Funding; BMS: Research Funding; Celgene: Research Funding; Medison: Research Funding; Gilead: Research Funding.
